Silo Pharma, INC S-1 registration statements

Silo Pharma, a biopharmaceutical and cryptocurrency treasury company, filed an S-1 registration statement for the resale of up to 3,071,428 common shares underlying previously issued warrants.

Silo Pharma updates its registration statement for a proposed offering of common stock, warrants, and pre-funded warrants to fuel its biopharmaceutical development.

Silo Pharma enters into an agreement with H.C. Wainwright & Co. to serve as the exclusive underwriter, agent, or advisor for any securities offerings during the term of the agreement.

Silo Pharma launches a public offering of common stock and warrants, aiming to raise approximately $4.3 million for working capital to support its biopharmaceutical development programs.

Silo Pharma has filed a registration statement for the resale of up to 820,911 shares of its common stock upon the exercise of outstanding warrants.

Silo Pharma, Inc. has filed an amendment to its S-1 registration statement, aiming to register 1,043,739 shares of common stock for resale, primarily issuable upon the exercise of warrants, with potential proceeds directed towards product development and general corporate purposes.

Silo Pharma is registering for the resale of up to 1,043,739 shares of its common stock by selling shareholders upon the exercise of outstanding warrants.